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PATIENTS AND METHODS

Demographic data:
Six patients (three male, three female, mean age: 40.5 years, minimum age: 27 years, maximum age: 52 years) with moderately to severely active UC, defined by the Clinical Activity Index (CAI according to Rachmilewitz 6 : 6-10), who have failed to achieve long-term remission with steroids and/or immunosuppressants or who were contraindicated or intolerant to steroids and/or immunosuppressants were recruited.
The
Immunopure ® (Nikkiso, Japan) device has been specifically designed to be used in a simple hemoperfusion setting for the removal of activated granulocytes, monocytes and platelets. The device is a gamma-ray sterilized single use (disposable) module filled with amorphous polyarylate resin beads of 1.0 mm diameter. The total volume is 350 mL. The void volume of the device is 139 mL.
Study design:
-Five treatment sessions at weekly intervals (week 1-5) with a treatment duration of 60 min -Blood flow of 30 mL/min, anticoagulation by standard heparin -Flow cytometry and enzyme-linked immunosorbent assay (ELISA, sCD40L) were performed during the 1 st , 3 rd and 5 th treatment session at baseline and at different time points from blood samples of the column inflow and outflow. -Blood from 8 healthy volunteers served as controls (seven female, one male, mean age:
41.1 years). -Disease activity: evaluated by assessing the CAI (10 weeks after the first apheresis treatment). Clinical remission in UC is defined as a CAI score of ≤ 4. Clinical response is defined as CAI drop ≥ 3 or CAI ≤ 4. Immunopure ® treatments were well tolerated and improved disease activity (67% remission, 83% response).
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Since UC is associated with abnormalities of platelet and leukocyte number and function, their reduction by apheresis with the Immunopure ® device seems to be related with disease improvement.
In addition to monocytes and granulocytes Immunopure ® is able to adsorb platelets, platelet aggregates and proinflammatory CD14 + CD16 + monocytes. The impact on efficacy parameters merits further evaluation in controlled trials and dose-finding studies with larger patient numbers. 
